Cost for fabrazyme?

Fabrazyme (agalsidase alfa) – cost overview

| Region | Typical annual cost (pre‑insurance) | Notes |
|--------|-------------------------------------|-------|
| United States | $300 000–$400 000 | Rough estimate for a 70 kg patient (≈$3,000 per infusion, 2‑weekly infusions). Prices can fluctuate due to contracts, rebates, and pharmacy benefit manager negotiations. |
| Canada | CAD 250 000–CAD 350 000 | Similar infusion schedule; cost varies by province and coverage plan. |
| European Union | €150 000–€250 000 | Prices differ by country; many have national formularies and negotiated discounts. |
| Australia | AUD 200 000–AUD 300 000 | Cost depends on Medicare rebates and private insurance. |

Key points

1. High cost – Fabrazyme is a specialty enzyme‑replacement therapy and is one of the more expensive drugs in the world.
2. Insurance & reimbursement – Most patients obtain coverage through national health programs, Medicare/Medicaid in the U.S., or private insurance. Reimbursement decisions often involve cost‑effectiveness analyses and may include special access programs.
3. Financial assistance – The manufacturer (Sanofi) offers patient assistance programs in several countries to help with copays, travel costs, or out‑of‑pocket expenses.
4. Variability – Prices can change with new pricing agreements, patent status, or market competition (e.g., the emergence of new Fabry treatments).

If you’re looking for the exact amount applicable to your specific insurance plan or country, it’s best to:

- Check with your insurer or pharmacy benefit manager.
- Contact the prescribing physician’s billing office – they often have up‑to‑date cost information and can guide you toward financial assistance if needed.
- Use official drug pricing portals (e.g., the Canadian Drug Price List, Medicare’s “Drug Pricing” tables, or EU’s European Medicines Agency pricing information).

---

Disclaimer: This information is intended as a general guide and may not reflect the most current prices or local variations. Always verify with your healthcare provider, insurer, or a qualified pharmacist before making any financial decisions.